DeJarnette departs IBM DIN-PACS consortiumDeJarnette Research Systems has decided to withdraw from the IBM consortium participating in the U.S. military's Digital Imaging Network-Picture Archiving and Communications Systems (DIN-PACS) deal. The
DeJarnette Research Systems has decided to withdraw from the IBM consortium participating in the U.S. military's Digital Imaging Network-Picture Archiving and Communications Systems (DIN-PACS) deal. The Towson, MD-based firm had been contributing its connectivity products to IBM as part of the team, but will no longer be involved in the engineering and product improvement plans on the project.
DeJarnette elected to withdraw from formal participation on the IBM team due to differences in corporate goals, technical direction, and business objectives between the two companies, said president Wayne DeJarnette. He declined to provide further details on the differences, other than to say that cultural differences between the companies led him to make the decision.
"We have decided it makes more business sense for us to participate with IBM as an OEM partner as opposed to a formal team member," he said.
The company said that its decision will not affect its relationships with Department of Defense customers, however. The company anticipates it will contribute its products on an OEM basis to IBM and will continue to sell products into other military accounts.
Although some analysts had estimated DIN-PACS spending to reach $165 million this year (PNN 6/98), actual awards to date have been under $35 million. This was not a factor in the decision to withdraw, however, DeJarnette said.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.